as of 12-31-2025 3:36pm EST
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 9.6B | IPO Year: | 1993 |
| Target Price: | $63.70 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.57 - $72.36 | Next Earning Date: | 02-09-2026 |
| Revenue: | $829,448,000 | Revenue Growth: | 23258.15% |
| Revenue Growth (this year): | -48.77% | Revenue Growth (next year): | -32.23% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Executive Officer
Avg Cost/Share
$69.01
Shares
51,726
Total Value
$3,575,574.78
Owned After
3,805,926
Director
Avg Cost/Share
$70.00
Shares
7,530
Total Value
$527,100.00
Owned After
69,053
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$68.59
Shares
12,586
Total Value
$861,339.86
Owned After
3,805,926
Director
Avg Cost/Share
$67.73
Shares
8,367
Total Value
$566,038.07
Owned After
62,514
Chief Executive Officer
Avg Cost/Share
$67.72
Shares
13,445
Total Value
$909,682.52
Owned After
3,805,926
Director
Avg Cost/Share
$67.66
Shares
10,040
Total Value
$679,491.34
Owned After
37,683
Director
Avg Cost/Share
$67.74
Shares
10,000
Total Value
$676,623.28
Owned After
33,600
Chief Executive Officer
Avg Cost/Share
$64.05
Shares
54,298
Total Value
$3,398,186.53
Owned After
3,805,926
Chief Executive Officer
Avg Cost/Share
$69.30
Shares
130,000
Total Value
$8,950,615.44
Owned After
3,805,926
Director
Avg Cost/Share
$61.03
Shares
16,250
Total Value
$991,737.50
Owned After
115,240
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Dec 29, 2025 | Sell | $69.01 | 51,726 | $3,575,574.78 | 3,805,926 | |
| Ferrari Mauro | ARWR | Director | Dec 26, 2025 | Sell | $70.00 | 7,530 | $527,100.00 | 69,053 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Dec 22, 2025 | Sell | $68.59 | 12,586 | $861,339.86 | 3,805,926 | |
| Waddill William D. | ARWR | Director | Dec 19, 2025 | Sell | $67.73 | 8,367 | $566,038.07 | 62,514 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Dec 19, 2025 | Sell | $67.72 | 13,445 | $909,682.52 | 3,805,926 | |
| Vakiener Victoria | ARWR | Director | Dec 19, 2025 | Sell | $67.66 | 10,040 | $679,491.34 | 37,683 | |
| OLUKOTUN ADEOYE Y | ARWR | Director | Dec 19, 2025 | Sell | $67.74 | 10,000 | $676,623.28 | 33,600 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Dec 16, 2025 | Sell | $64.05 | 54,298 | $3,398,186.53 | 3,805,926 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Dec 15, 2025 | Sell | $69.30 | 130,000 | $8,950,615.44 | 3,805,926 | |
| PERRY MICHAEL S | ARWR | Director | Dec 5, 2025 | Sell | $61.03 | 16,250 | $991,737.50 | 115,240 |
See how ARWR stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ARWR Arrowhead Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.